AbCellera Biologics Inc.
ABCL
$4.24
-$0.23-5.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -16.14% | -22.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.14% | -22.39% | |||
| Cost of Revenue | -7.77% | 12.47% | |||
| Gross Profit | 6.74% | -19.05% | |||
| SG&A Expenses | -0.50% | -13.99% | |||
| Depreciation & Amortization | 127.43% | -152.64% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 46.04% | -54.27% | |||
| Operating Income | -53.75% | 56.49% | |||
| Income Before Tax | -13.14% | 25.23% | |||
| Income Tax Expenses | 41.65% | -9.49% | |||
| Earnings from Continuing Operations | -33.36% | 33.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.36% | 33.06% | |||
| EBIT | -53.75% | 56.49% | |||
| EBITDA | -120.13% | 54.10% | |||
| EPS Basic | -32.30% | 33.18% | |||
| Normalized Basic EPS | -71.60% | 61.36% | |||
| EPS Diluted | -32.30% | 33.18% | |||
| Normalized Diluted EPS | -71.60% | 61.36% | |||
| Average Basic Shares Outstanding | 0.74% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.74% | 0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||